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Abstract
Introduction: Vagus nerve stimulation (VNS) is an adjunct therapy to anti-epileptics in patients 
where combination drug therapy alone has failed. The VNS device resembles an implantable 
defibrillator, and can be found underneath the clavicle on either side of the chest. By using 
a strong ring magnet, the device can be manipulated to seize function or operate on higher 
intensities, depending on how it is applied. The use of vagal stimulation is increasingly common 
and VNS is being explored for a range of other medical complaints. 
Case: This case study discusses the encounter between a paramedic and a woman presenting with 
a choking sensation, isolated uvular deviation and stable cardiorespiratory functions. Following a 
short period of observation without adverse events, she was discharged on scene and advised to 
see her specialist epilepsy nurse.
Conclusion: Side effects of VNS increase with intensity of stimulation and can manifest 
throughout any branch of the vagus nerve. Its therapeutic mechanism of action is yet to be fully 
understood. The symptoms of over-stimulation are often frightening but benign, and although 
life-threatening events are rare, they require rapid recognition and immediate intervention.
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Vagus nerve stimulation (VNS) is a palliative adjunct 
therapy used in some of the 280,000 to 320,000 people 
suffering from epilepsy in the United Kingdom (UK) 
(Booth & Thompson, 2010; Scottish Intercollegiate 
Guidelines Network (SIGN), 2015). VNS is considered 
when seizure absence is unsuccessful after two appropri-
ate drug therapies have been tried, and in those where 
curative resection of the brain is not suitable or has failed 
(Dalic & Cook, 2016; Ghaemi et al., 2010; National Insti-
tute of Health and Care Excellence, 2012; SIGN, 2015). 
VNS is also used together with other anti-epileptic inter-
ventions such as callostomy (separating the corpus cal-
losum) and deep brain stimulation. Vagus stimulation 
therapy is a recognised therapy for epilepsy but it is also 
being researched for use in a range of other conditions 
within mental and somatic healthcare (Vale et al., 2011; 
Yuan & Silberstein, 2015).
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side, as the contralateral branch has been thought to more 
dominantly affect the cardiorespiratory systems, but Krahl 
(2012) deems this as dogma stemming from studies in ani-
mals with different vagus nerve anatomy to humans. Yuan 
and Silberstein (2015) support this and affirm right-sided 
VNS as equally efficacious in arresting seizure activity. 
Arrhythmias are not uncommon in implantation of 
VNS, with an occurrence rate of asystole in the implan-
tation of a left-sided VNS equalling 1 in 1000 (Krahl, 
2012). Despite this, no authors have reported on fatal 
asystole outside of the operating theatre. In similar fash-
ion to AICDs, the vagus stimulator is terminated by hold-
ing a strong magnet over the device, but can in contrast 
also be triggered to enhance stimuli by swiping a mag-
net across it, i.e. when a patient perceives an aura – a fea-
ture not applicable to defibrillators (Deyell et al., 2010; 
Fisher et al., 2014; Ramani, 2008).
Vagus stimulation has been found to reduce frequency 
and intensity of seizures in 50–80% of patients, but its 
exact mechanism of action is not fully understood (Chras-
tina et al., 2018; Englot et al., 2011; García-Navarrete 
et al., 2013). Granbichler et al. (2015) were unable to es-
tablish its efficacy in reducing mortality, but linked VNS 
to an increased risk of premature death as this therapy is 
dominant in patients with an already volatile and poorly 
controlled seizure illness. It is not thought that VNS it-
self affects these numbers either way. A study published 
by Chrastina et al. (2018) looked at patients followed up 
after long-term therapy. This found that VNS effectively 
maintains seizure control, but also that many initial VNS 
non-responders achieved a reduction of seizures after the 
two-year follow-up.
Looking at adverse effects of VNS, contrasting low- 
and high-level stimulation, Panebianco et al. (2015) as-
serted dysphonia and dyspnoea as the two most common 
adverse effects. Additional side effects identified include 
cough, pain, paresthesia, nausea, headache and torticollis 
(Al Omari et al., 2017). Ardesch et al. (2010) reported vo-
cal cord affection as a negative side effect occurring even 
at sub-therapeutic amplitude levels. Krahl (2012) later 
argued that dysphonia and coughing are reproducible in 
anyone when VNS is applied. This is due to the nerve’s 
role in controlling the pharynx and larynx, hence why the 
patient in this case study demonstrated deviation of the 
uvula on overstimulation. Most literature describes these 
side effects as benign, albeit bothersome and frightening. 
Conversely, Bhatt et al. (2010) report on a presenta-
tion of a threatened airway following seizures and incre-
mentally stronger vagus stimulation. As parasympathetic 
stimuli increase, so does the risk of unwanted cholinergic 
upper respiratory effects such as glottal and vocal cord 
dysfunction, or lower respiratory effects such as bron-
choconstriction. Adverse cardiovascular effects can take 
the form of bradycardia or asystole, and their significance 
cannot be overstated despite a low number of documented 
cases (Cantarín-Extremera et al., 2016; Fleisher et al., 
2011). A case study by Iriarte et al. (2009) reports on a 
woman experiencing asystolic syncopes as a result of her 
Case presentation
A 39-year-old woman contacted the ambulance service 
stating that she was choking. On assessment by the at-
tending paramedic, she was sat upright on the sofa, ap-
peared systemically well but was distressed. She had a 
patent airway, although her uvula was deviated to the left. 
She had a hoarse voice and was unable to talk properly. 
She confirmed that she had a sensation of choking, but 
had good bilateral air entry on examination with no ad-
ditional sounds. Her physiological observations were all 
normal and a 3-lead electrocardiogram showed a sinus 
rhythm of 70 beats per minute. 
On further assessment, an implanted device under the 
patient’s left clavicle was discovered, which turned out 
to be a VNS. As the patient’s condition spontaneously 
improved, she explained that she had experienced a ‘tin-
gling’ sensation in her throat. She had interpreted this as 
the onset of a seizure, so had swiped her ring magnet to 
activate the VNS. However, the ‘tingling’ sensation had 
become worse, leading to a cycle of further VNS activa-
tions with the magnet and worsening of symptoms un-
til she was unable to speak and felt as though she was 
choking.
The paramedic provided reassurance and advice, and 
on learning that the patient did not feel confident about 
using her device, advised her to contact her specialist 
neurology team the next day for follow-up and further 
advice. Now understanding that the choking sensation 
was a common side effect and nothing to worry about, 
the patient was content with the management plan.  The 
patient was not transported to hospital, so the treating 
paramedic added that she or anyone around her should 
still call for help if she had a seizure leading to injury, a 
seizure lasting more than five minutes or repeat seizures 
without recovery in between (BMJ Best Practice, 2020).
Discussion
The tenth cranial nerve consists of a roughly 20/80 per-
cent composition of motor and sensory fibres respec-
tively (Ruffoli et al., 2011). Exiting the brainstem on both 
sides, trailing down the carotid arteries towards the abdo-
men it innervates the pharynx, larynx, cardiorespiratory 
organs and the gastrointestinal tract. Its functions include 
parasympathetic control of most internal organs, but even 
more so providing sensory information about the body’s 
internal environment to the brain, controlling neurologi-
cal and endocrine responses (Krahl, 2012). The cervical 
segments are asymmetrical in that the right nerve com-
municates to the sinoatrial node (reducing heart rate), 
while the left branch commands the atrioventricular node 
(suppressing conduction). Exploiting this physiology, 
VNS makes use of an implantable device similar to an 
automatic implanted cardioversion defibrillator (AICD). 
A VNS presents as a distinctive solid mass in the infra-
clavicular region on either side depending on which vagal 
branch it is applied to. This will most often be the left 
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Vagus stimulation is also used in mood disorders and 
is being considered for application in an array of other 
conditions; therefore, it is reasonable to assume that para-
medics are increasingly likely to encounter these patients 
in the community. The management of these patients is 
not clearly defined in the literature. Treatment and thera-
pies must be based on knowledge on pathophysiology and 
pharmacology and translated from existing guidelines for 
treating the presenting symptoms. In a patient presenting 
with a threatened airway, oxygen therapy in conjunction 
with bronchodilators and non-invasive ventilation proved 
efficacious in palliation of adverse effects in one subject, 
but it was ultimately termination of the vagus stimulation 
that restored airway stability (Bhatt et al., 2010). In the 
absence of recommendations on managing these patients 
in extremis, it is felt that early consideration for contact-
ing senior medical advice to optimise management of 
these patients is necessary.
Little literature exists on severe adverse events, and the 
vast majority of side effects are provoking or frightening 
but nevertheless benign. Underlying knowledge about the 
autonomic nervous system, cranial nerve examination, 
correlating pathophysiology and VNS therapy can equip 
the paramedic to provide reassurance and advice, as well 
as managing a patient presenting in extremis. Epileptics 
receiving VNS will generally be allocated to a neurology 
specialist or team that can provide advice or an opportu-
nity for onwards referral and follow-up. It could be ar-
gued that any side effect significant enough to cause 999 
activation should as a bare minimum be communicated 
to the specialist team to flag up the event. Clearer guid-
ance on the management of those with a VNS and adverse 
signs and symptoms is currently lacking but could enable 
paramedics to make confident management plans when 
encountering this rare patient group.
‘Take-home’ messages
•	 The number of people living with epileptic VNS 
therapy is increasing
•	 VNS is also used in people with mood disor-
ders, and has a potential role in a range of other 
pathologies
•	 Most side effects of VNS are bothersome but do 
not require immediate intervention
•	 Life-threatening adverse events such as severe 
asthma-like symptoms, or bradycardia or asys-
tole can occur, albeit very rarely
•	 Successful therapy appears to rely on identifi-
cation of an implanted VNS device, discontinu-
ation of stimuli and symptomatic treatment of 
cholinergic effects
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